Guidelines on the use of finasteride in androgenetic alopecia

Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia.

BACKGROUND Finasteride, a type II-selective 5alpha-reductase inhibitor, as a causative agent of decreasing dihydroxy testosterone (DHT) level, is effective in the treatment of male androgenic alopecia. AIM We compared the local and oral finasteride in the treatment of androgenic alopecia. METHOD This is a double blind, randomized clinical trial study of 45 male patients, who were referred w...

Androgenetic Alopecia

Guidelines for the management of androgenetic alopecia (2010).

Guidelines for the management of androgenetic alopecia (2010) Ryoji TSUBOI, Satoshi ITAMI, Shigeki INUI, Rie UEKI, Kensei KATSUOKA, Sotaro KURATA, Takeshi KONO, Norimitsu SAITO, Motomu MANABE, Masashi YAMAZAKI, GUIDELINES PLANNING COMMITTEE FOR THE MANAGEMENT OF ANDROGENETIC ALOPECIA Department of Dermatology, Tokyo Medical University, Tokyo, Department of Regenerative Dermatology, Osaka Univer...

Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men.

Dihydrotestosterone (DHT) binding to androgen receptors (AR) in hair follicles is commonly accepted as the first step leading to the miniaturizing of follicles associated with androgenetic alopecia (AGA). Testosterone is converted to DHT by the enzyme 5alpha-reductase. Finasateride a 5alpha-reducase inhibitor blocks the production of DHT and is currently used to treat AGA. The inhibition is not...

Minoxidil vs finasteride in the treatment of men with androgenetic alopecia.

BACKGROUND Androgenetic alopecia (male pattern hair loss) is caused by androgen-dependent miniaturization of scalp hair follicles, with scalp dihydrotestosterone (DHT) implicated as a contributing cause. Finasteride, an inhibitor of type II 5alpha-reductase, decreases serum and scalp DHT by inhibiting conversion of testosterone to DHT. OBJECTIVE Our purpose was to determine whether finasterid...